Boston Scientific announced positive six-month results from the SIMPLAAFY trial testing two single-drug therapies against the standard dual anti-platelet therapy (DAPT) after WATCHMAN FLX Pro device implantation in patients with non-valvular atrial fibrillation. Both aspirin alone and reduced-dose NOAC regimens proved non-inferior to DAPT in preventing strokes, with less bleeding and lower clotting rates. These findings suggest simpler, safer post-procedure drug regimens may be possible, improving patient care and reducing medication burden. The trial continues to 12 months to confirm long-term outcomes.
Boston Scientific Corporation (BSX) shares rose 5.03% to USD 44.09 on Pluang, showing strong investor interest despite trading well below its 52-week high of USD 104.98. The stock's market cap stands at $60.84 billion, with a typical hold time of 82 days among Pluang users. These figures are current as of Nov 03, 2026 02:11 WIB.
